LINC01119: A Potential Drug Target and Biomarker (G100134259)

Target Name: LINC01119

NCBI ID: G100134259

LINC01119

Other Name(s): Long intergenic non-protein coding RNA 1119 | long intergenic non-protein coding RNA 1119

LINC01119: A Potential Drug Target and Biomarker

LINC01119 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the potential drug targets of LINC01119, its potential as a biomarker, and its current status in the scientific community.

Potential Drug Targets

LINC01119 has been shown to interact with several protein molecules, including Focal Adhesion Assay (FAA) proteins. FAA proteins are involved in cell adhesion and play a role in various diseases, including cancer. Therefore, LINC01119 may be a potential drug target for cancer treatment.

In addition to its interaction with FAA proteins, LINC01119 has also been shown to interact with several other proteins, including the protein known as PD-L1. PD-L1 is a protein that is expressed in many types of cancer and has been shown to promote cancer cell growth and survival. LINC01119 may be a potential drug target for cancer treatment by inhibiting the activity of PD-L1.

Biomarker Potential

LINC01119 has also been shown to serve as a biomarker for various diseases, including cancer. Its expression has been shown to increase in various types of cancer, including breast, ovarian, and prostate cancer. This increase in LINC01119 expression may be used as a diagnostic biomarker for these diseases.

In addition to its use as a biomarker, LINC01119 may also be used as a therapeutic target. Its interaction with PD-L1 has been shown to promote cancer cell growth and survival, which may make it a potential target for cancer treatment. Additionally, LINC01119 has also been shown to interact with the protein known as EGFR, which is involved in the development and progression of various types of cancer. Therefore, LINC01119 may be a potential drug target for cancer treatment by inhibiting the activity of EGFR.

Current Status in the Scientific Community

LINC01119 is a relatively new molecule that has been shown to play a role in various diseases, including cancer. While more research is needed, the potential drug targets and biomarkers of LINC01119 are being investigated.

In cancer treatment, LINC01119 may be used as a potential drug target by inhibiting the activity of PD-L1 or by inhibiting the interaction between LINC01119 and EGFR. Further research is needed to determine the efficacy and safety of these treatments.

Conclusion

In conclusion, LINC01119 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its interaction with FAA proteins and PD-L1 has been shown to play a role in various diseases, including cancer. Further research is needed to determine the potential therapeutic benefits and risks of targeting LINC01119. If proven to be safe and effective, LINC01119 may be a valuable tool for cancer treatment.

Protein Name: Long Intergenic Non-protein Coding RNA 1119

The "LINC01119 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01119 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets